P62 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis
Titel:
P62 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis
Auteur:
Puoti, Massimo Foster, Graham Wang, Stanley Mutimer, David Gane, Edward Moreno, Christophe Tsung Chang, Ting Lee, SamS Marinho, Rui DuFour, Jean-Francois Pol, Stanislas Hezode, Christophe Gordon, Stuart C. Strasser, Simone I. Thuluvath, Paul J. Liu, Ran Pilot-Matias, Tami Mensa, Federico